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High Fluorodeoxyglucose Uptake on Positron EmissionTomography
in Patients with Advanced Non^Small Cell Lung Cancer on
Platinum-Based Combination Chemotherapy
Kyung-Hun Lee,1Se-Hoon Lee,1,3 Dong-Wan Kim,1,3 WonJun Kang,2 June-Key Chung,2 Seock-Ah Im,1,3
Tae-You Kim,1,3 YoungWhan Kim,1Yung-Jue Bang,1,3 and Dae Seog Heo1,3
Abstract Purpose: To evaluate response and survival for platinum-based combination chemotherapy in
chemonaive patients with non ^ small cell lung cancer (NSCLC) according to pretreatment stan-
dardized uptake values (SUV) by fluorodeoxyglucose positron emission tomography.
Experimental Design: Patients with advanced NSCLC who had not previously received
chemotherapy were eligible. Response rates and survivals were analyzed according to maximal
SUVs [low (V7.5) versus high (>7.5), where 7.5 was the median value] before the first cycle of
chemotherapy.
Results: Eighty-five consecutive patients were included in the retrospective study. Patients with
high SUV tumors exhibited significantly higher response rates (34.1% for low SUVs versus 61.0%
for high SUVs; P = 0.013). Other factors, including sex, age, histology, performance status,
number of involved organs, regimens used, and disease stage, did not affect response. However,
high SUVswere relatedwith a shorter response duration (279 days for low SUVs versus141days
for high SUVs; P = 0.003) and time to progression (282 days for low SUVs versus 169 days for
high SUVs;P =0.015). Overall survivalwasunaffectedbymaximal SUVs (623 days for lowSUVs
versus 464 days for high SUVs; P = 0.431).
Conclusions: Patients having NSCLC with high maximal SUVs showed a better response to
platinum-based combination chemotherapy but had a shorter time to progression.Tumor glucose
metabolism, as determined by SUVs on fluorodeoxyglucose positron emission tomography, was
found to discriminate NSCLC subsets with different clinical and biological features.
Primary lung cancer is the leading cause of cancer deaths in
Korea as well as in the United States (1, 2). Two thirds of
patients with newly diagnosed non–small cell lung cancer
(NSCLC) have inoperable disease, including locally advanced
or metastatic tumors, and many patients who undergo curative
surgery suffer from recurrent NSCLCs (3). Platinum-based
chemotherapy is a well-established first-line therapy in the
palliative setting for patients with advanced disease, as it
improves the quality of life and prolongs overall survival (4, 5).
High glucose metabolism is a unique feature of tumor cells,
which is reflected by standardized uptake values (SUV) as
measured by positron emission tomography (PET) using [18F]-
fluorodeoxyglucose (FDG). NSCLC also shows increased
glucose metabolism, and FDG-PET has improved the manage-
ment of NSCLC in several ways. The detection of lymph nodes
and distant metastases by FDG-PET are more sensitive and
specific than by conventional methods (6). In addition,
reduced metabolic activity during chemotherapy as measured
by FDG-PET is correlated with response to chemotherapy and
allows the early prediction of treatment outcome and patient
survival (7).
Previous reports have shown that high FDG uptake as
measured by SUVs is correlated with tumor proliferative rates in
NSCLC (8) as well as in other various types of malignancies
(9–11). On the other hand, FDG-PET imaging has been shown
to provide a highly reproducible measure of metabolism
(12, 13). Therefore, it is likely that tumor metabolism measured
by PET is related to response to chemotherapy in patients with
NSCLC because chemotherapeutic agents are directed against
dividing cells. The relation between initial SUV before
treatment and subsequent response to chemotherapy, however,
has not been well investigated. Most previous studies about PET
and chemotherapy focus rather on the early prediction of
response using differences between SUVs before and after
treatment.
Thus, we retrospectively investigated response and survival
for platinum-based chemotherapy in chemonaive patients
with advanced NSCLCs according to pretreatment SUVs on
FDG-PET.
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Patients andMethods
Patients. Among the patients with pathologically proven NSCLC at
Seoul National University Hospital (Seoul, Korea) from September
1999 to June 2005, those who had undergone an FDG-PET scan and
had received platinum doublets as first-line chemotherapy were
analyzed. Patients with locally advanced or metastatic disease,
including brain metastases, or recurrence after curative surgery were
eligible, but patients who had received neoadjuvant or adjuvant
chemotherapy were excluded. The full list of patients with NSCLC
who underwent PET scan was retrospectively drawn from the electronic
archive of the institution, and 85 patients met the inclusion/exclusion
criteria. The main purpose of PET scan was staging work-up for possible
resection and identification of recurrence after surgery. The PET scan
results did not influence selection of chemotherapy regimens.
Initial staging work-ups of the patients included computed tomog-
raphy of the chest and upper abdomen and bone scintigraphy. Cerebral
magnetic resonance imaging was done if clinical symptoms suggested
the presence of brain metastases. Previous palliative radiation therapy at
symptomatic sites was permitted, including whole-brain radiotherapy,
provided that the indicator sites (the sites that were followed to
determine maximal SUVs or whether there was a response) had not
been irradiated and that the radiation therapy had been completed
before chemotherapy was initiated. Patients with recurrent disease after
curative radiotherapy were not included in this study. Three patients
had received adjuvant radiotherapy after curative surgery, but the
indicator sites had not been irradiated. The median time from the date
of PET scan to the date of the first chemotherapy was 8 days. The
performance statuses of the patients were 0 to 2 on the Eastern
Cooperative Oncology Group scale.
Chemotherapy and response evaluation. The chemotherapy regimens
used in the present study included paclitaxel (145 mg/m2) and cisplatin
(60 mg/m2) in 42 patients, paclitaxel (135 mg/m2) and carboplatin
(area under the curve, 5) in 18, gemcitabine (1,250 mg/m2) and
cisplatin (60 mg/m2) in 9, vinorelbine (25 mg/m2) and cisplatin (80
mg/m2) in 6, docetaxel (75 mg/m2) and cisplatin (70 mg/m2) in 6,
gemcitabine (1,200 mg/m2) and carboplatin (area under the curve, 5)
in 3, and etoposide (100 mg/m2) and cisplatin (75 mg/m2) in 1. Dose
reductions were allowed at the discretion of the treating physician.
Chest X-rays and serum tumor markers, if elevated, were taken every
cycle of chemotherapy, and computed tomography scans were taken
every two cycles if other means showed no disease progression. Tumor
response was evaluated by the treating physician according to WHO
criteria and independently reviewed by another diagnostic radiologists
(14). Time to progression (TTP) was calculated from the date of the
initiation of chemotherapy to the date of progression or death.
Response duration was calculated from the date of confirmation of
response to the date of progression. Overall survival was calculated
from the date of initiation of chemotherapy until the date of death or
the date when the patient was last known to be alive. Forty-six patients
received second-line chemotherapy, seven patients palliative radiother-
apy, and one patient palliative surgery followed by chemotherapy, after
the first chemotherapy.
FDG-PET imaging. Whole-body FDG-PET was done using the same
scanner, ECAT-EXACT 47 PET scanner (CTI/Siemens, Knoxville, TN).
For attenuation correction, transmission scanning with triple germani-
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Primary tumor 69 (81.2)
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Distant metastasis 5 (5.9)
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V7.5 44 15 34.1 0.013
>7.5 41 25 61.0
Sex
Male 66 28 42.4 0.111
Female 19 12 64.2
Histopathology
Adenocarcinoma 38 18 47.4 0.959
Others 47 22 46.8
Performance status
0 or1 78 38 48.7 0.439
2 7 2 28.6
Location of themaximal
SUV
Primary tumor 69 32 46.4 0.794
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Cisplatin based 64 28 43.8 0.286
Carboplatin based 21 12 57.1
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patient had fasted for at least 6 hours, [18F]-FDG (370-555 MBq) was
injected i.v. After 60 minutes, whole-body images were obtained for
6 minutes for each bed. Transaxial images were reconstructed using
a Shepp-Logan filter (cutoff frequency, 0.35 cycles per pixel) and
corrected for attenuation using the attenuation map obtained from the
transmission images.
The SUV was calculated from the amount of FDG injected, body
weight, and soft tissue uptake in the attenuation-corrected regional
images: SUV = (activity / unit volume) / (injected dose / body weight).
Region of interest was drawn manually around tumor area on
transaxial section of FDG-PET image. Because maximal SUV showed
higher reproducibility than that of mean SUV, maximal SUV was
chosen for analysis. Maximal SUV was defined as the peak SUV value on
one pixel with the highest counts within region of interest.
We measured maximal SUVs of all the lesions, such as lymph nodes
or distant metastasis, found on FDG-PET images, but the lesion chosen
for analysis was the one with the highest SUV. Therefore, maximal SUV
was the highest SUV in the patient. Patients with brain metastases were
included in this study, but brain metabolism was not chosen for the
analysis.
Statistical analysis. The statistical analyses of categorical variables
were done using Pearson’s m2 test or Fisher’s exact test, as appropriate.
Median durations of TTP and overall survival were calculated using the
Kaplan-Meier method, and comparisons between groups were made
using log-rank tests. Multivariate logistic regression analysis was carried
out using the Cox proportional hazards model. A significance level of
0.10 was used for covariate entry. Two-sided Ps < 0.05 were considered
significant. All analyses were done using SPSS for Windows, version
12.0 (SPSS, Inc., Chicago, IL).
Ethics. The study protocol was reviewed and approved by the
institutional review board of Seoul National University Hospital. The
recommendations of the Declaration of Helsinki for biomedical
research involving human subjects were also followed.
Results
Patient characteristics. A total of 85 patients were included in
the study, and they were divided into two groups according to
maximal SUVs; V7.5 and >7.5, where 7.5was equal to themedian
value of the maximal SUVs of 85 patients studied. Forty-four
patients had tumors of low SUV (V7.5) and 41 had tumors of
high SUV (>7.5). Patient characteristics are presented in Table 1.
Response rates according to maximal SUVs. Forty of 85
patients responded to first-line chemotherapy with an overall
response rate of 47%. Patients with high SUV tumors exhibited
significantly higher response rates to first-line platinum-based
chemotherapy (34.1% for low SUV versus 61.0% for high SUV;
P = 0.013). Other factors, including sex, age, histology,
performance status, number of involved organs, regimens used,
and whether in an advanced or recurrent setting, did not affect
response (Table 2). Maximal SUV and other factors that might
influence the response were included in the multivariate
analysis, and high SUV was an independent factor with a
higher response rate (Table 3). The separate analysis of 68
patients excluding 17 recurrent cases also revealed higher
response rate for high SUV tumors (33.3% for low SUV versus
57.9% for high SUV; P = 0.044).
The response to chemotherapy according to initial maximal
SUVs are presented in Table 4. Sixty-one percent of patients
with a high SUV showed response to chemotherapy. Interest-
ingly, half of the patients with a low SUV had stable disease
after first-line chemotherapy.
TTP and overall survival according to maximal SUVs. Median
TTP for the 85 patients was 200 days [95% confidence interval
(95% CI), 132-268]. TTP was significantly shorter in patients
with tumors with a high SUV (169 days; 95% CI, 135-203)
than in patients with a low SUV (282 days; 95% CI, 203-361;
P = 0.015; Fig. 1). Multivariate analysis showed that a high SUV
was a predictor of shorter TTP (hazard ratio, 0.429; 95% CI,
0.224-0.822). Interestingly, differences according to SUV were
significant in both responder and nonresponder subgroups. Of
those patients that responded to first-line chemotherapy,
median TTPs were 351 days (95% CI, 304-398) for patients
with a low SUV and 181 days (95% CI, 149-213) for those with
a high SUV (P = 0.004). Of those that did not respond, median
TTPs were 193 days (95% CI, 86-300) for patients with a low
SUV and 71 days (95% CI, 66-76) for those with a high SUV
(P = 0.006; Fig. 2).
Response duration also was significantly shorter in patients
with high SUVs. Median response durations were 279 days
(95% CI, 214-344) for patients with a low SUV and 141 days
(95% CI, 102-180) for those with a high SUV (P = 0.003).
Overall survival was not affected by initial maximal SUV (623
days for low SUV versus 464 days for high SUV; P = 0.431;
Fig. 1).
Discussion
The present study shows that tumors with a high pretreat-
ment SUV respond better to first-line platinum-based doublet
chemotherapy in chemonaive patients with NSCLC. But,
responses were rather transient, and TTPs and response
durations were significantly shorter for those with a high SUV.
Table 3. Multivariate analysis of response rates by
logistic regression
Odds ratio (95% CI) P
Maximal SUV (V7.5) 0.220 (0.076-0.638) 0.005




Chemotherapy setting (recurrent) 1.829 (0.531-6.301) 0.339
Table 4. Response to platinum-based combination chemotherapy according to the maximal SUV
Response to chemotherapy Partial response (%) Stable disease (%) Progressive disease (%) Total
Maximal SUV
V7.5 15 (34.1) 22 (50.0) 7 (15.9) 44
>7.5 25 (61.0) 7 (17.0) 9 (22.0) 41
Total 40 (47.1) 29 (34.1) 16 (18.8) 85
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Generally, tumors responding to chemotherapy are believed
to be associated with a longer TTP. However, our data suggest
that tumors with a high SUV respond to chemotherapy initially
but then rapidly progress. In contrast, tumors with a low SUV
did not show a marked response but progressed rather slowly.
Table 4 provides an explanation of this phenomenon. Half of
our patients with a low SUV had stable disease, which have
been a consequence of the slow growth. On the other hand, the
higher response rate of tumors with a high SUV may have been
the result of rapid proliferation.
It has been shown that SUV, measured by FDG-PET, correlates
with the immunohistochemistry of Ki-67 (a proliferation index
marker) in NSCLC and lesion doubling time in lung tumors
(8, 15). Moreover, higher Ki-67 was associated with better
response to chemotherapy in early or locally advanced breast
cancer (16–18). Thus, higher response rates in patients with
higher SUVs can be explained in terms of the rapid proliferation
of tumor cells and the effectiveness of the chemotherapy against
proliferating cells. However, other biological factors influencing
chemosensitivity, such as apoptosis, are not evaluated in this
study and should be included together in the future study.
Response rates are often considered as a surrogate end point
for survival in patients with advanced cancers, such as NSCLC
(19). However, our results show that patients who show
response to chemotherapy do not necessarily have a longer TTP
or overall survival. Instead, it should be pointed out that
patients who responded were heterogeneous, and some had
relatively short TTPs and overall survivals. However, FDG-PET
can aid in identifying patients who shows discordance between
response rate and survival.
Previous reports about SUVs and responses to chemotherapy
have focused on changes in the glucose metabolism before and
after chemotherapy. Early prediction of response was found
to be possible from SUV changes in various types of cancers
Fig. 1. Kaplan-Meier plots ofTTP (A), response duration (B), and overall survival
(C) according to pretreatment maximal SUVs.
Fig. 2. Kaplan-Meier plots ofTTP (A) and overall survival (B) for responder and
nonresponder subgroups to first-line chemotherapy.
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(7, 20–26). However, the relationship between pretreatment
SUVs and subsequent response seems to be uncertain based on
this series of studies.
An interesting example is provided by the study of Wieder
et al. (25), which included 38 patients with esophageal
squamous cell carcinoma. An analysis of the raw data presented
in the report produced results that agreed with those of the
present study. Excluding 5 patients not evaluable for histo-
pathologic response, 12 of 16 patients with high SUVs (>9.08,
where 9.8 is the median) responded histopathologically
(response rate, 75.0%), whereas 7 of 17 patients with low
SUVs (V9.08) did (response rate, 41.2%; P = 0.08, Fisher’s exact
test). Considering the relatively small number of patients, this
finding is in clear accordance with our results.
The raw data in the study by Smith et al. (20), which
included 31 tumors in 30 patients with locally advanced breast
cancer, can be similarly analyzed. Taking the higher dose
uptake ratio value from breast lesions or axillary lymph nodes,
the median dose uptake ratio was 0.0904. Six of 15 (40.0%)
tumors with a high dose uptake ratio (>0.0904) showed
microscopic complete pathologic response, whereas only 1 of
16 (6.3%) tumors with a low dose uptake ratio (V0.0904) did
(P = 0.037, Fisher’s exact test).
In another report about colorectal carcinoma, it was
concluded that pretreatment SUV was predictive with respect
to therapy outcome (96% for progressive disease and 47% for
stable disease), although partial remission could not be
predicted exactly (24). These results support the possibility
that pretreatment glucose metabolism measured by FDG-PET is
related to subsequent response to chemotherapy in NSCLC.
In our analysis, the overall response rate was 47% (40 of 85),
and median TTP was 200 days (95% CI, 132-268), which seems
better than those of previously reported clinical trials (4, 19).
One possible explanation is that not all patients who had been
diagnosed in the hospital where this study was conducted
underwent a PET scan. The main purpose of PET scan was
staging work-up for possible resection and identification of
recurrence after surgery. In addition, PET might have upstaged
patients more so than conventional studies, such as chest
computed tomography scan or bone scintigraphy, and early
detection of metastases by PET might have led to apparently
better survival in NSCLC patients, perhaps due to potential bias
like lead-time bias.
The cutoff point of the maximal SUV used in the present
study is 7.5, which was the median value of SUVs of the
patients. Previous reports about the prognostic significance of
SUVs in NSCLC have used various cutoff values from 7 to 10
(27, 28). Analysis using the cutoff point of 10 also gave similar
results from the 85 patients (response rate, 38.3% for SUV
V10.0 versus 68.0% for SUV >10.0; P = 0.013; TTP, 267 days
versus 149 days; P = 0.009; response duration, 272 days versus
141 days; P = 0.005; overall survival, 626 days versus 419 days;
P = 0.064). Appropriate cutoff values, however, remains to be
investigated in future research.
In conclusion, patients having NSCLC with high maximal
SUVs showed a better response to platinum-based combination
chemotherapy but had a shorter TTP. Tumor glucose metab-
olism, as determined by SUVs on FDG-PET, was found to
discriminate NSCLC subsets with different clinical and
biological features.
Imaging, Diagnosis, Prognosis
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